A review on treatment of Alzheimer’s disease
Article Main
Abstract
Alzheimer’s disease is a brain disorder named after German physician Alois Alzheimer, who first described it in 1906. The Alzheimer’s disease is now becoming curable by identifying the actual cause of the disease with the proper diagnosis of the disease of the patient. The disease can now be cured by drug treatment, by hormonal treatment and by using herbal products such as medicines. The drugs are based on antagonizing action of the components against the causative agents (â Amyloid plaque, Apolipoprotein E, Tau protein) of the disease. The
common drugs based on their action are N-methyl-D-aspartate (NMDA) receptor antagonists, Cholinesterase inhibitor, agents for increasing blood supply and neurotransmitter in the brain, lipofuchsin and â Amyloid plaque inhibitor, free radical scavenger, agent for metal chelator and agent for increasing macrophage activity in the brain.
Article Details
Article Details
Alzheimer’s disease, Memantine, Hydergine, Rivastigmine tartrate, Turmeric
Benke, T. (1993). Two forms of apraxia in Alzheimer’s disease. Cortex, 29 (4): 715–25.
Brookmeyer, R., Johnson, E., Ziegler-Graham, K. and MH, Arrighi. (2007). Forecasting the global burden of Alzheimer’s disease . Alzheimer’s and Dementia, 3 (3): 186–91.
Calabrese, V., Butterfield, DA. and Stella, AM. (2003). Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer’s disease. Ital. J. Biochem., 52(4):177-81.
Chen, X., Gawryluk, J.W. Wagener, J.F., Ghribi, O. and Geiger, J.D. (2008). Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer’s disease. The Journal of Neuroinflammation, vol.5.
Danysz, W. and Parsons, C.G. (2003).The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. International journal of Geriatric psychiatry, 18: S23-S32.
Fiala, M., Liu, P.T., Espinosa-Jeffrey, A., Rosenthal, M.J., Bernard, G., Ringman, J.M., Sayre, J., Zhang, L., Zaghi J., Dejbakhsh, S., Chiang, B., Hui, J., Mahanian, M., Baghaee, A., Hong, P. and Cashman, J. (2007). Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. U S A, 104(31):12849-54.
Förstl, H. and Kurz, A. (1999). Clinical features of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience, 249 (6): 288–290.
Goodman, Y., Bruce, A.J., Cheng, B. and Mattson, M.P. (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem , 66:1836-44.
Hernandez, F. and Avila, J. (2007). Tauopathies. Cell. Mol. Life Sci., 64 (17): 2219–33.
Kappus, H. and Diplock, A.T. (1992). Tolerance and safety of vitamin E: a toxicological position report. Free Radic BiolMed, 13:55-74.
Kemppainen, N.M., Aalto, S. and Karrasch, M., (2008). Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease. Ann. Neurol., 63 (1): 112–8.
Femke. M.S. Devrij, Jacquilina A. Sluijs Luisa Gregore, David F. Fischer, Wim T. J.M.C., Hermens, Dmitry, Goldgaver,Joost Verhaagen, Fred W.Van Leeuwan and Elly M. Hol. (2001) Mutant ubiquitin expressed in Alzheimer’s Disease causes neuronal death. The FASEB Journal, 15:2680-2688.
Lott, I.T. and Head, E. (2005). Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging, 26 (3): 383–89.
Oyama, Y., Chikahisa, L., Ueha, T., Kanemaru, K. and Noda, K. (1996). Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Research, 712:349-352.
Spiegel, R. (1983). A controlled long term study with Hydergine, in healthy elderly volunteers. Journal of the American Geriatrics Society, 31: 549-555.
Tiraboschi, P., Hansen, L.A., Thal, L.J. and Corey-Bloom, J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 62 (11): 1984–9.
This work is licensed under Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) © Author (s)
